A5077801946- Cancer Immunotherapy and Biomarkers
- Melanoma and MAPK Pathways
- Immunotherapy and Immune Responses
- CAR-T cell therapy research
- Lung Cancer Research Studies
- Traumatic Brain Injury Research
- Cancer, Stress, Anesthesia, and Immune Response
- Traumatic Brain Injury and Neurovascular Disturbances
- Inhalation and Respiratory Drug Delivery
- Cutaneous Melanoma Detection and Management
- Cardiac Arrest and Resuscitation
- Protein Degradation and Inhibitors
Vanderbilt University Medical Center
2017-2024
Vanderbilt University
2024
Vanderbilt-Ingram Cancer Center
2024
Background Artificial intelligence (AI) chatbots have become a major source of general and medical information, though their accuracy completeness are still being assessed. Their utility to answer questions surrounding immune-related adverse events (irAEs), common potentially dangerous toxicities from cancer immunotherapy, not well defined. Methods We developed 50 distinct with answers in available guidelines 10 irAE categories queried two AI (ChatGPT Bard), along an additional 20...
Identifying patients likely to benefit from immune checkpoint inhibitor (ICI) treatment remains a crucial goal for melanoma. The objective of this study is assess the association between primary tumor features and immunotherapy response survival in advanced melanoma patients. In single-center retrospective cohort study, disease characteristics, immunotherapy, PFS, OS were assessed among (excluding mucosal uveal primaries) treated with ICI. Among 447 patients, 300 (67.1%) received anti-PD-1...
9520 Background: Immune checkpoint inhibitors (ICI) targeting PD-1 and CTLA-4 can achieve durable responses. Historically, therapies in advanced malignancies were considered palliative, however long-term results from ICI melanoma studies suggest cure may be possible for some patients (pts). Despite clinical trial data, little is known about the risk, character, outcome of late recurrences after ICI. Methods: treated pts with who had a disease control, defined as not requiring subsequent line...